In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA ...
(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...
This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...
Pharmaceutical Technology on MSN
CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug
The pair will work together to progress lixudebart across multiple rare kidney and liver diseases.
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Guggenheimanalyst Vamil Divan maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at ...
Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 1 / 12 Episodes Total]IntroductionLigand Pharmaceuticals ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Join Us at the Blue Hope Bash to Support the Fight Against Colorectal Cancer / Blue Hope Bash Committee, cancer, colorectal ...
Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in ...
Today, the American Kidney Fund (AKF) is convening its seventh annual national summit on Unknown Causes of Kidney Disease (UCKD) in Washington, D.C., bringing healthcare professionals, researchers, ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alpha Cognition Inc (ACOG) and Travere Therapeutics (TVTX) with bullish sentiments. According to TipRanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results